JPWO2021136263A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021136263A5 JPWO2021136263A5 JP2022540754A JP2022540754A JPWO2021136263A5 JP WO2021136263 A5 JPWO2021136263 A5 JP WO2021136263A5 JP 2022540754 A JP2022540754 A JP 2022540754A JP 2022540754 A JP2022540754 A JP 2022540754A JP WO2021136263 A5 JPWO2021136263 A5 JP WO2021136263A5
- Authority
- JP
- Japan
- Prior art keywords
- immune effector
- effector cell
- gene
- cell according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 35
- 239000012642 immune effector Substances 0.000 claims 28
- 229940121354 immunomodulator Drugs 0.000 claims 28
- 108091033409 CRISPR Proteins 0.000 claims 10
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 8
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 101150118346 HLA-A gene Proteins 0.000 claims 5
- 108020005544 Antisense RNA Proteins 0.000 claims 4
- 238000010354 CRISPR gene editing Methods 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000003184 complementary RNA Substances 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 101150076800 B2M gene Proteins 0.000 claims 2
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010002929.3 | 2020-01-02 | ||
| CN202010002929 | 2020-01-02 | ||
| PCT/CN2020/140799 WO2021136263A1 (zh) | 2020-01-02 | 2020-12-29 | 一种经修饰的免疫效应细胞及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508740A JP2023508740A (ja) | 2023-03-03 |
| JPWO2021136263A5 true JPWO2021136263A5 (zh) | 2023-12-28 |
Family
ID=76559305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540754A Pending JP2023508740A (ja) | 2020-01-02 | 2020-12-29 | 修飾された免疫エフェクター細胞及びその調製方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220193135A1 (zh) |
| EP (1) | EP4086342A4 (zh) |
| JP (1) | JP2023508740A (zh) |
| KR (1) | KR20220124197A (zh) |
| CN (2) | CN115003802A (zh) |
| AU (1) | AU2020418199B2 (zh) |
| CA (1) | CA3163304A1 (zh) |
| WO (1) | WO2021136263A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112852748B (zh) * | 2020-04-16 | 2023-11-21 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| WO2023274384A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向b7h3的抗原结合多肽及其应用 |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| WO2023151620A1 (zh) * | 2022-02-09 | 2023-08-17 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| WO2024094165A1 (zh) * | 2022-11-04 | 2024-05-10 | 茂行制药(苏州)有限公司 | 靶向b7h3的通用型car-t细胞及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| CA2964953A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in cart cells and uses thereof |
| BR112018011089A2 (pt) * | 2015-12-04 | 2018-12-04 | Intellia Therapeutics Inc | composições e métodos para a imuno-oncologia |
| US20180325955A1 (en) * | 2017-05-12 | 2018-11-15 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN107630006B (zh) * | 2017-09-30 | 2020-09-11 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
-
2020
- 2020-12-29 WO PCT/CN2020/140799 patent/WO2021136263A1/zh unknown
- 2020-12-29 CA CA3163304A patent/CA3163304A1/en active Pending
- 2020-12-29 EP EP20911252.3A patent/EP4086342A4/en active Pending
- 2020-12-29 CN CN202080090688.0A patent/CN115003802A/zh active Pending
- 2020-12-29 KR KR1020227026014A patent/KR20220124197A/ko unknown
- 2020-12-29 AU AU2020418199A patent/AU2020418199B2/en active Active
- 2020-12-29 CN CN202011605256.7A patent/CN113061580B/zh active Active
- 2020-12-29 JP JP2022540754A patent/JP2023508740A/ja active Pending
-
2021
- 2021-12-28 US US17/563,804 patent/US20220193135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210348166A1 (en) | Immunotherapy of cancer | |
| AU2020230334A1 (en) | Compositions and methods for immunooncology | |
| US20200016202A1 (en) | Modulation of novel immune checkpoint targets | |
| AU2022271376A1 (en) | CRISPR/CAS-related methods and compositions for treating herpes simplex virus | |
| US20190255107A1 (en) | Modulation of novel immune checkpoint targets | |
| US20220257794A1 (en) | Circular rnas for cellular therapy | |
| CA3118824A1 (en) | Anti-liv1 immune cell cancer therapy | |
| US20230061936A1 (en) | Methods of dosing circular polyribonucleotides | |
| JP4517061B2 (ja) | ダンベル型ｄｎａの効率的な製造方法 | |
| CA3134944A1 (en) | Engineered mrna sequences and uses thereof | |
| JP2023179428A (ja) | メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸 | |
| CN115361954A (zh) | 用于翻译的组合物及其使用方法 | |
| KR20230117174A (ko) | 핵산을 세포에 전달하기 위한 조성물 및 방법 | |
| US20090012016A1 (en) | Short Interfering Rna and Micro-Rna Compounds and Methods of Designing, Making, and Using the Same | |
| JPWO2021136263A5 (zh) | ||
| KR20230079367A (ko) | 핵산을 세포에 전달하기 위한 조성물 및 방법 | |
| CN111902532A (zh) | 用于癌症治疗的精氨酸酶抑制 | |
| JPWO2020163365A5 (zh) | ||
| US11053503B2 (en) | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | |
| CN113874042A (zh) | 病毒感染及活性抑制方法 | |
| JP2022541212A (ja) | 治療的使用のための、ヒト遺伝子ＪＡＫ１又はＪＡＫ３の発現を標的とするＳｉＲＮＡ配列 | |
| JPWO2020092850A5 (zh) | ||
| EP4370676A2 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| WO2023212687A1 (en) | Systems for enhancing mrna expression and uses thereof |